Effets de la chirurgie bariatrique sur la mortalité des patients suédois obèses

Sjostrom, L.; Narbro, K.; Sjostrom, C.D.; Karason, K.; Larsson, Bertil; Wedel, H. von; Lystig, Theodore C.; Sullivan, M.; Bouchard, C.; Carlsson, Bodil; Bengtsson, Calle; Dahlgren, S; Gummesson, Anja; Jacobson, P.; Karlsson, Josefin; Lindroos, A.K.; Lönroth, Henrik; Näslund, I; Olbers, Torsten; Stenlof, K.; Torgerson, J.; Ågren, G.; Carlsson, Lena

doi:10.1016/s0021-7697(08)70286-2

Cited by 2 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The differences are mainly explained by disparate weight changes occurring in the two groups during a delay between matching and baseline measurements: during the waiting time for bariatric surgery (on average more than 1 year), participants awaiting surgery tended to gain weight and control subjects tended to lose weight. 12 Figure 1 shows changes in BMI in patients without baseline heart failure for up to 20…”

Section: Baseline Characteristics and Changes In Weightmentioning

confidence: 99%

“…10 The Swedish Obese Subjects (SOS) study is an ongoing controlled intervention trial that compares the effects of bariatric surgery and conventional obesity care on morbidity and mortality. 11 The SOS study has found that bariatric surgery, as a primary preventive strategy, reduces mortality 12 and cardiovascular morbidity 13 in obesity. The purpose of this report is to describe the effect of bariatric surgery on the incidence of new-onset heart failure.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Surgical obesity treatment and the risk of heart failure

Jamaly

Carlsson

Peltonen

et al. 2019

European Heart Journal

View full text Add to dashboard Cite

Aims Obesity is associated with increased risk for heart failure. We analysed data from the Swedish Obese Subjects (SOS) study, a prospective matched cohort study, to investigate whether bariatric surgery reduces this risk. Methods and results From the total SOS population (n = 4047), we identified 4033 obese individuals with no history of heart failure at baseline, of whom 2003 underwent bariatric surgery (surgery group) and 2030 received usual care (control group). First-time principal diagnoses of heart failure were identified by crosschecking the SOS database with the Swedish National Patient Register and the Swedish Cause of Death Register using diagnosis codes. During a median follow-up of 22 years, first-time heart failure occurred in 188 of the participants treated with surgery and in 266 of those receiving usual care. The risk of developing heart failure was lower in the surgery group than in the control group [sub-hazard ratio 0.65, 95% confidence interval (CI) 0.54–0.79; P < 0.001]. After pooling data from the two study groups, the quartile of subjects with the largest weight loss after 1 year (mean −41 kg) displayed the greatest risk reduction (sub-hazard ratio 0.51, 95% CI 0.30–0.70; P < 0.001). This association remained statistically significant after adjustment for surgical intervention and potential baseline confounders (sub-hazard ratio 0.60, 95% CI 0.36–0.97; P = 0.038). Conclusion Compared with usual care, bariatric surgery was associated with reduced risk of heart failure among persons being treated for obesity. The risk of heart failure appeared to decline in parallel with a greater degree of weight loss. ClinicalTrials.gov Identifier NCT01479452.

show abstract

Section: Baseline Characteristics and Changes In Weightmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Surgical obesity treatment and the risk of heart failure

Jamaly

Carlsson

Peltonen

et al. 2019

European Heart Journal

View full text Add to dashboard Cite

show abstract

“…Orlistat (a pancreatic lipase inhibitor) and naltrexone-bupropion are the only licensed medications in the UK for obesity and substantial side effects limit patient compliance, other agents are licensed in the USA but are not approved in Europe (Figure 1) (7). Bariatric surgery can successfully treat obesity (8), however these procedures are invasive, can cause significant complications and are not suitable for everyone. There has been less effort on the development of pharmacotherapy to specifically increase EE (energy balance equation; Figure 1).…”

Section: Introductionmentioning

confidence: 99%

MECHANISMS IN ENDOCRINOLOGY: Human brown adipose tissue as a therapeutic target: warming up or cooling down?

McNeill

Suchacki

Stimson

2021

European Journal of Endocrinology

View full text Add to dashboard Cite

Excessive accumulation of white adipose tissue leads to obesity and its associated metabolic health consequences such as type 2 diabetes and cardiovascular disease. Several approaches to treat or prevent obesity including public health interventions, surgical weight loss, and pharmacological approaches to reduce caloric intake have failed to substantially modify the increasing prevalence of obesity. The (re-)discovery of active brown adipose tissue (BAT) in adult humans approximately 15 years ago led to a resurgence in research into whether BAT activation could be a novel therapy for the treatment of obesity. Upon cold stimulus, BAT is activated and generates heat to maintain body temperature, thus increasing energy expenditure. Activation of BAT may provide a unique opportunity to increase energy expenditure without the need for exercise. However, much of the underlying mechanisms surrounding BAT activation are still being elucidated and the effectiveness of BAT as a therapeutic target has not been realised. Research is ongoing to determine how best to expand BAT mass and activate existing BAT; approaches include cold exposure, pharmacological stimulation using sympathomimetics, browning agents that induce formation of thermogenic beige adipocytes in white adipose depots, and the identification of factors secreted by BAT with therapeutic potential. In this review, we discuss the caloric capacity and other metabolic benefits from BAT activation in humans and the role of metabolic tissues such as skeletal muscle in increasing energy expenditure. We discuss the potential of current approaches and the challenges of BAT activation as a novel strategy to treat obesity and metabolic disorders.

show abstract

Effets de la chirurgie bariatrique sur la mortalité des patients suédois obèses

Cited by 2 publications

References 18 publications

Surgical obesity treatment and the risk of heart failure

Surgical obesity treatment and the risk of heart failure

MECHANISMS IN ENDOCRINOLOGY: Human brown adipose tissue as a therapeutic target: warming up or cooling down?

Contact Info

Product

Resources

About